Helping Lupus Patients and Clinicians Talk About Taking Medicines
Tests a communication program helping adults with lupus discuss missed medication doses.
Plain-language title generated from the registry record
Registry title: Intervention to Improve Communication and Medication Adherence in Lupus
Key facts
- Where
- Durham, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT06458075, who can take part
Where in United States
- Duke UniversityDurham, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Duke University
- Trial code
- NCT06458075
- Record updated
- 17 August 2026
- Original description
CO-LEAD is an intervention to improve patient-provider communication and medication adherence among patients with systemic lupus erythematosus (SLE).Read full original descriptionShow less
Intervention to Improve Patient-provider Communication and Medication Adherence Among Patients With Systemic Lupus Erythematosus (SLE)
CO-LEAD is an intervention to improve patient-provider communication and medication adherence among patients with systemic lupus erythematosus (SLE).
The purpose of this study is to optimize the culturally appropriate delivery and test the effect of the CO-LEAD intervention, which includes the following:
1. clinicians will be provided with a program to teach them to use effective communication strategies with patients to review real-time pharmacy refill date, engage and formulate solutions to adherence barriers, and collaboratively overcome adherence barriers. 2. use of a reliable and valid patient-reported measure of the extent of and reasons for nonadherence that helps patients identify and communicate their adherence barriers with clinicians proactively, efficiently, and comprehensively.
Clinician Inclusion Criteria:; Adult rheumatology attendings, advanced practice providers, and fellows at the two academic institutions; Clinicians who have ambulatory rheumatology care at least ½ day per week; Clinician Exclusion Criteria:; Clinicians at Duke University who were involved in the investigators' pilot work; Clinicians with an anticipated departure from the institution in the 12 months following enrollment; Patient Inclusion Criteria:; 18 years or older; English-speaking, able to provide consent; Diagnosed with SLE and receiving care with enrolled clinicians; Prescribed at least one SLE medication, and filling their SLE mediations at a pharmacy linked to Surescripts reporting visible in Epic EMR; Patient Exclusion Criteria:; Non-English speakers; Patients who are prescribed only corticosteroids for SLE; Patients who are accompanied by third-party member that is not willing or able to remain in the waiting room during the patient's visit and; Does not wish to be audio recorded; A minor without a parental/legal guardian and/or; Unable to give consent.